Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alkem Laboratories Ltd gains for third consecutive session
Alkem Laboratories Ltd is quoting at Rs 5680, up 1.46% on the day as on 12:49 IST on the NSE. The stock is up 18.31% in last one year as compared to a 4.13% drop in NIFTY and a 16.41% drop in the Nifty Pharma index.
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row - Mint
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a rowMint
Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block deal
Shares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece on Tuesday. Promoter-linked entities offloaded their stake, while domestic mutual funds and foreign institutional investors emerged as key buyers, signalling strong institutional participation. The company also launched semaglutide pre-filled syringes in India.
Stocks to Watch, June 3: Alkem Labs, Dhanuka Agritech, Paytm, Canara Bank
Stocks to Watch today, June 3: Infosys, Alkem Labs, Paytm among others in focus; here's why
Stocks in news: Alkem Labs, Vedanta, Canara Bank, NHPC, Adani Ports
Markets closed higher on weekly expiry day despite volatility, with Nifty showing signs of recovery but facing resistance around 23,800-24,000. Key stocks like Alkem Labs, Vedanta, Canara Bank, NHPC, and Adani Ports are in focus due to significant corporate developments including block deals, ED visits, capital raising plans, oversubscribed OFS, and strong cargo volumes.
Alkem Labs sees Rs 930 crore block deal as promoter family entities pare stake; Goldman, Morgan Stanley among key buyers
Alkem Laboratories shares experienced significant block deals totaling Rs 930 crore. Promoter family entities divested shares to a group of domestic mutual funds and foreign institutional investors. This transaction occurred after a strong performance by Alkem Laboratories shares over the past year. The deal highlights continued institutional interest in the pharmaceutical sector.
Alkem launches India’s first ready-to-use semaglutide syringe for diabetes and weight loss from ₹350
The launch comes as India grapples with rising diabetes and obesity cases, offering patients another treatment option designed to improve long-term adherence.
Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss
Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordable for diabetes and obesity management. The company is the first in India to offer this convenient format. This move intensifies competition in the growing Indian drug market. Alkem aims to expand access to quality medicines for better patient care.
Stocks to Watch, June 2: NHPC, Alkem Labs, Wipro, Paytm, Ola Electric
Stocks to Watch, June 2: L&T, Anant Raj, Ola Electric, Paytm, Alkem Labs among shares to remain on investors' and traders' radar today
Stocks to Watch Today: Alkem Labs, Ola Electric, PNC Infratech, Equitas Small Finance Bank, NHPC, Anant... - Moneycontrol.com
Stocks to Watch Today: Alkem Labs, Ola Electric, PNC Infratech, Equitas Small Finance Bank, NHPC, Anant...Moneycontrol.com
Stocks to Watch today: RIL, Lupin, Wipro, Asian Paints, Ireda,Tata Elxsi
Stocks to Watch today, May 29, 2026: Ashok Leyland, Alkem Laboratories, PhysicsWallah, GMR Airports, InterGlobe Aviation, NMDC, and Glenmark Pharma are among the top stocks to remain in focus today
Alkem Labs Q4 Results: Net Profit Declines 28% As One-Time Loss Weighs; Dividend Declared — Check Record Date
Consolidate revenue of Alkem Labs advanced by 14.6% year-on-year for the three months ended March, reaching Rs 3,603 crore in comparison to Rs 3,144 crore.